Excelsior Biopharma (6496) — Cash Flow Quality Index
Excelsior Biopharma (6496) has a Cash Flow Quality Index of -3.02x as of December 2023. Operating cash flow of NT$-25.78 Million is below net income of NT$8.54 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Excelsior Biopharma cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Excelsior Biopharma Cash Flow Quality Index (2017–2020)
Historical Cash Flow Quality Index for Excelsior Biopharma across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Excelsior Biopharma investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Excelsior Biopharma (2017–2020)
Year-by-year earnings quality comparison for Excelsior Biopharma. For live market cap and the full company financial profile, see market cap of Excelsior Biopharma.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 11.50x | NT$520.81 Million | NT$45.30 Million | ▲ +581.0% |
| 2019 | -2.39x | NT$-169.74 Million | NT$71.01 Million | ▼ -517.8% |
| 2018 | 0.57x | NT$126.92 Million | NT$221.83 Million | ▼ -54.2% |
| 2017 | 1.25x | NT$349.47 Million | NT$279.68 Million | — |